Placeholder

Insights from the C-Suite: Pharmaceutical Companies

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

The pharmaceutical industry is facing a number of well-publicized challenges: increasing generic competition, pricing pressures, innovation hurdles, Wall Street scrutiny, etc. C-suite pharmaceutical executives who were also featured in the PharmaVOICE 100 provide their insights on what they believe are the biggest challenges they as well as the industry face.

According to IMS Health, overall per capita use of medicines declined in 2011 as patient office visits and non-emergency room hospital admissions dropped, and older Americans reduced their retail drug use. Not only were rates of usage for chronic medicines declining, there were important variations across the country and by patients’ age, which suggests a concerning trend in the nation’s use of healthcare services. Young people, age 19 to 25, increased their use of prescription drugs as many were able, for the first time, to remain on their parents’ health insurance, while seniors, age 65 and over, reduced their…

Experts
Lisa Costantino
, Chief Financial Officer, EMD Serono. For more information, visit emdserono.com
Elliot Ehrich, M.D., Senior VP, Research and Development, Chief Medical Officer, Alkermes Inc. For more information,
visit alkermes.com.
Karen Ferrante, M.D., Chief Medical Officer, Millennium: The Takeda Oncology Company.  For more information, visit ­
millennium.com.
Marie Foegh, M.D., Chief Medical Officer, VP Clinical Research & Development, Agile Therapeutics. For more information, visit agiletherapeutics.com.
Adelene Perkins, President and CEO, Infinity Pharmaceuticals Inc. For more information, visit infi.com.
Timothy Wright, M.D., Global Head of Pharma Development, Novartis AG. For more information, visit novartis.com.

 

FEEDBACK